HS-20089
Phase 3Small molecule
HS-20089 is one of 77 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.
2
Indications
4
Total Trials
4
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Piqray
NovartisPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Pamiparib
BeiGenePhase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Karenitecin
BBioNumerik Pharmaceuticals, Inc.
Phase 3
JSKN003
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
AZD5335
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-20089. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHansoh BioMedical R&D Company